Sinopharm Tech Holdings Limited (08156.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	90.3M	61.3M	41.3M	42.8M	41.0M
Cost of Revenue	73.4M	47.7M	36.3M	37.4M	35.1M
Gross Profit	16.9M	13.5M	5.0M	5.5M	5.1M
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	26.0M	20.6M	14.2M	22.0M	42.4M
General & Admin Expense	17.0M	19.4M	13.7M	19.8M	41.4M
Selling & Marketing Expense	2.5M	1.6M	495.0K	2.3M	1.0M
Other Expenses	(3.0M)	—	1.2M	(1.4M)	(6.4M)
Total Operating Expenses	23.1M	20.6M	15.4M	20.6M	36.0M
Cost and Expenses	96.5M	68.4M	52.9M	133.6M	99.0M
Operating Income (EBIT)	(6.1M)	(7.1M)	(9.2M)	(90.8M)	(58.0M)
Non-Operating
Interest Income	1.0K	3.0K	84.0K	2.0K	3.0K
Interest Expense	4.6M	5.9M	23.9M	8.6M	16.4M
Net Interest Income	(6.9M)	(5.9M)	(23.8M)	(8.6M)	(16.4M)
Other Non-Op Income/Expense	7.5M	6.0M	(11.2M)	79.9M	(36.1M)
Non-Operating Income (excl Interest)	(7.6M)	(11.9M)	(12.8M)	2.8M	3.1M
EBT (Pre-Tax Income)	1.4M	(1.1M)	(20.3M)	(10.8M)	(94.2M)
Income Tax Expense	570.5K	291.0K	83.0K	(1.3M)	(387.0K)
Bottom Line
Net Income	3.3M	(867.0K)	(19.7M)	(10.6M)	(88.0M)
Earnings from Cont. Ops	819.0K	(1.4M)	(20.4M)	(9.5M)	(93.8M)
Earnings from Discont. Ops	—	—	388.0K	(558.0K)	—
Bottom Line Net Income	4.7M	(867.0K)	(20.1M)	(10.6M)	(88.0M)
Per Share
Basic EPS	HK$0.01	(HK$0.00)	(HK$0.11)	(HK$0.06)	(HK$0.49)
Diluted EPS	HK$0.01	(HK$0.00)	(HK$0.11)	(HK$0.06)	(HK$0.49)
Revenue Per Share	HK$0.14	HK$0.13	HK$0.22	HK$0.23	HK$0.23
Shares
Basic Shares Outstanding	633.7M	464.8M	183.7M	182.9M	179.9M
Diluted Shares Outstanding	633.7M	464.8M	183.7M	182.9M	179.9M
Profitability Metrics
EBITDA	2.9M	6.1M	5.0M	(1.0M)	(75.2M)
D&A	1.5M	1.3M	1.4M	2.0M	2.4M
EBIT	1.4M	4.8M	3.6M	(3.0M)	(77.7M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025